Eloxx Pharmaceuticals, Inc.
Research Eloxx Pharmaceuticals, Inc. (ELOX) on Bullrun: market cap USD 50.21M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerELOX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 50.21M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 4.50M
- Free cash flow-USD 4.79M
Valuation Snapshot
latest market cap is USD 50.21M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 6.00M | -USD 6.33M | n/a | -5.39 | USD 4.79M | USD 1.00M | -USD 11.91M |
| FY2024 | USD 6.36M | -USD 3.14M | -USD 4.72M | n/a | -9.24 | USD 111.00K | USD 6.52M | -USD 24.34M |
| FY2023 | USD 0 | -USD 17.05M | -USD 14.34M | n/a | -72.93 | USD 1.13M | USD 3.83M | -USD 22.60M |
| FY2022 | USD 0 | -USD 36.07M | -USD 31.91M | n/a | -183.15 | USD 19.21M | USD 12.54M | -USD 10.66M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 50.21M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.27K | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.46K | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 41.49M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 43.37M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 673.10M | n/a | n/a | n/a |
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Eloxx Pharmaceuticals, Inc.'s market cap?
Eloxx Pharmaceuticals, Inc.'s market capitalization is USD 50.21M.
What does Eloxx Pharmaceuticals, Inc. do?
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia.